Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MYR-101,Levetiracetam,Prednisone
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Myrtelle Reports NAA Reduction in Phase 1/2 Gene Therapy Trial For Canavan Disease
Details : MYR-101 (rAAV-Olig001-ASPA) is a gene therapy candidate, which is intended to restore ASPA function and brain development in patients with Canavan Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : MYR-101,Levetiracetam,Prednisone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MYR-101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Myrtelle’s Gene Therapy Lowers Key Biomarker in Canavan Disease
Details : MYR-101 (rAAV-Olig001-ASPA) is a gene therapy candidate, which is intended to restore ASPA function and brain development in patients with Canavan Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : MYR-101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MYR-101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Myrtelle: FDA Selects rAAV-Olig001-ASPA for Canavan START Program
Details : MYR-101 (rAAV-Olig001-ASPA) is a gene therapy candidate, which is intended to restore ASPA function and brain development in patients with Canavan Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : MYR-101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rAAV-Olig001-ASPA is the first gene therapy designed to target the oligodendrocytes, which are critical for myelination and nerve function. Therepy reduces N-Acetylaspartate concentration, allowing myelination to occur. It is currently being investigated...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
January 09, 2023
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rAAV-Olig001-ASPA is a novel vector from a class of recombinant AAVs that selectively target oligodendrocytes–the cells in the brain responsible for producing myelin, the insulating material that enables proper function of neurons and makes up the brai...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 04, 2022
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Myr-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Recipient : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership
Details : Forge will provide research-grade and GMP-Pathway plasmid manufacturing services as well as cGMP adeno-associated viral (AAV) process development and scale-up manufacturing services for Myrtelle’s program, Myr-201 (gene therapy delivery of a therapeuti...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : Myr-201
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Recipient : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Myrtelle Announces Exclusive Worldwide Gene Therapy Licensing Agreement for Canavan Disease
Details : Following the licensing agreement, Myrtelle is now conducting a first-in-human Phase I/II clinical study for CD under an open U.S. Investigational New Drug (IND) AVASPA.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 14, 2021
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Details : RAAV-Olig001-ASPA is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Canavan Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 06, 2021
Lead Product(s) : rAAV-Olig001-ASPA
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable